GTBP Stock Catalyst: GT Biopharma Submitted IND Application for GTB-5550 TriKE

Jan 14, 2026 · 6:29pm ET

Company seeks FDA approval for B7-H3-targeted NK cell engager.

Max move

+31.9%

High of day $0.87

Sparker timei

6:29pm ET

GTBP · Jan 14, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

GT Biopharma, Inc. announced on January 15, 2026 GT Biopharma announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for the treatment of B7-H3 expressing solid tumor cancers.

The announcement cited ~$7M.

GT Biopharma Inc. Common Stock has a free float of 9,801,400 shares and 10,636,100 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GTBP sparks.

Download Sniper App →

Catch the next GTBP-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →